0001512762 false 0001512762 2025-11-13 2025-11-13 0001512762 2022-01-01 2022-12-31 0001512762 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2024-12-31 0001512762 us-gaap:DomesticCountryMember us-gaap:ResearchMember 2024-12-31 0001512762 us-gaap:AdditionalPaidInCapitalMember chrs:AtMarketOfferingMember 2024-01-01 2024-12-31 0001512762 us-gaap:AdditionalPaidInCapitalMember chrs:PublicOfferingMember 2023-01-01 2023-12-31 0001512762 us-gaap:AdditionalPaidInCapitalMember chrs:OptionalStockPurchaseAgreementMember 2023-01-01 2023-12-31 0001512762 us-gaap:AdditionalPaidInCapitalMember chrs:AtMarketOfferingMember 2023-01-01 2023-12-31 0001512762 chrs:OptionalStockPurchaseAgreementMember 2023-01-01 2023-12-31 0001512762 srt:MaximumMember chrs:AtMarketOfferingMember 2022-11-08 2022-11-08 0001512762 us-gaap:CommonStockMember chrs:AtMarketOfferingMember 2024-01-01 2024-12-31 0001512762 chrs:ChiefMarketingOfficerMember chrs:OptionalStockPurchaseAgreementMember 2023-10-09 2023-10-09 0001512762 chrs:PublicOfferingMember 2023-05-16 2023-05-16 0001512762 us-gaap:CommonStockMember chrs:PublicOfferingMember 2023-01-01 2023-12-31 0001512762 us-gaap:CommonStockMember chrs:OptionalStockPurchaseAgreementMember 2023-01-01 2023-12-31 0001512762 us-gaap:CommonStockMember chrs:AtMarketOfferingMember 2023-01-01 2023-12-31 0001512762 us-gaap:RetainedEarningsMember 2024-12-31 0001512762 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001512762 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001512762 us-gaap:RetainedEarningsMember 2023-12-31 0001512762 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001512762 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001512762 us-gaap:RetainedEarningsMember 2022-12-31 0001512762 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001512762 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001512762 chrs:ChiefMarketingOfficerMember chrs:OptionalStockPurchaseAgreementMember 2023-10-09 0001512762 us-gaap:OverAllotmentOptionMember 2023-05-16 0001512762 us-gaap:CallOptionMember 2020-04-14 0001512762 2020-04-14 0001512762 chrs:ExercisePriceRangeTwoMember 2024-01-01 2024-12-31 0001512762 chrs:ExercisePriceRangeThreeMember 2024-01-01 2024-12-31 0001512762 chrs:ExercisePriceRangeSixMember 2024-01-01 2024-12-31 0001512762 chrs:ExercisePriceRangeOneMember 2024-01-01 2024-12-31 0001512762 chrs:ExercisePriceRangeFourMember 2024-01-01 2024-12-31 0001512762 chrs:ExercisePriceRangeFiveMember 2024-01-01 2024-12-31 0001512762 srt:ChiefExecutiveOfficerMember us-gaap:PerformanceSharesMember 2024-01-01 2024-12-31 0001512762 srt:ChiefExecutiveOfficerMember chrs:PerformanceBasedVestingOptionsMember 2024-01-01 2024-12-31 0001512762 srt:ChiefExecutiveOfficerMember chrs:MarketConditionVestingOptionsMember 2024-01-01 2024-12-31 0001512762 chrs:ExercisePriceRangeTwoMember 2024-12-31 0001512762 chrs:ExercisePriceRangeThreeMember 2024-12-31 0001512762 chrs:ExercisePriceRangeSixMember 2024-12-31 0001512762 chrs:ExercisePriceRangeOneMember 2024-12-31 0001512762 chrs:ExercisePriceRangeFourMember 2024-12-31 0001512762 chrs:ExercisePriceRangeFiveMember 2024-12-31 0001512762 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001512762 chrs:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2023-01-01 2023-12-31 0001512762 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001512762 chrs:TwoThousandTenPlanMember 2014-01-01 2023-12-31 0001512762 srt:MinimumMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-12-31 0001512762 srt:MaximumMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-12-31 0001512762 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0001512762 us-gaap:ProductAndServiceOtherMember 2024-01-01 2024-12-31 0001512762 chrs:ToripalimabMember 2024-01-01 2024-12-31 0001512762 us-gaap:ProductAndServiceOtherMember 2023-01-01 2023-12-31 0001512762 chrs:ToripalimabMember 2023-01-01 2023-12-31 0001512762 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:EmployeeSeveranceMember 2023-01-01 2023-12-31 0001512762 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeSeveranceMember 2023-01-01 2023-12-31 0001512762 us-gaap:EmployeeSeveranceMember 2023-03-10 2023-03-10 0001512762 chrs:TermLoansMember us-gaap:SegmentContinuingOperationsMember 2024-05-08 2024-05-08 0001512762 chrs:TermLoansMember us-gaap:SegmentDiscontinuedOperationsMember 2024-04-01 2024-04-01 0001512762 chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member 2025-04-15 2025-04-15 0001512762 chrs:BiopharmaCreditInvestmentsVGpLlcMember chrs:TermLoansMember 2024-05-08 2024-05-08 0001512762 us-gaap:SegmentDiscontinuedOperationsMember 2024-12-31 0001512762 us-gaap:SegmentContinuingOperationsMember 2024-12-31 0001512762 srt:MinimumMember us-gaap:ComputerEquipmentMember 2024-12-31 0001512762 srt:MaximumMember us-gaap:ComputerEquipmentMember 2024-12-31 0001512762 2022-04-01 2022-04-30 0001512762 chrs:PublicOfferingMember 2023-05-18 2023-05-18 0001512762 chrs:PublicOfferingMember 2023-01-01 2023-12-31 0001512762 chrs:YusimryImmunologyFranchiseMember 2024-01-01 2024-12-31 0001512762 chrs:CimerliOphthalmologyFranchiseMember 2024-01-01 2024-12-31 0001512762 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-12-31 0001512762 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001512762 us-gaap:StateAndLocalJurisdictionMember 2024-12-31 0001512762 us-gaap:DomesticCountryMember 2024-12-31 0001512762 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0001512762 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001512762 chrs:AccruedRebatesFeesAndReservesMember 2024-12-31 0001512762 chrs:AccruedRebatesFeesAndReservesMember 2023-12-31 0001512762 chrs:NewCamarilloLeaseMember 2023-01-01 2023-12-31 0001512762 chrs:CorporateHeadquartersLeaseAgreementMember 2023-01-01 2023-12-31 0001512762 us-gaap:CostOfSalesMember chrs:UdenycaMember 2024-01-01 2024-12-31 0001512762 chrs:UdenycaMember 2024-01-01 2024-12-31 0001512762 us-gaap:CostOfSalesMember chrs:YusimryProductMember 2023-01-01 2023-12-31 0001512762 chrs:TermLoansMember us-gaap:SegmentDiscontinuedOperationsMember 2024-01-01 2024-12-31 0001512762 chrs:TermLoansMember us-gaap:SegmentContinuingOperationsMember 2024-01-01 2024-12-31 0001512762 chrs:TermLoansMember us-gaap:SegmentDiscontinuedOperationsMember 2023-01-01 2023-12-31 0001512762 chrs:TermLoansMember us-gaap:SegmentContinuingOperationsMember 2023-01-01 2023-12-31 0001512762 chrs:OutLicensesWithNovartisInstitutesMember 2024-01-01 2024-03-31 0001512762 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember chrs:YusimryImmunologyFranchiseMember 2024-06-26 2024-06-26 0001512762 chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member 2025-04-01 2025-06-30 0001512762 chrs:BiopharmaCreditInvestmentsVGpLlcMember chrs:TermLoansMember 2024-01-01 2024-12-31 0001512762 us-gaap:LicensingAgreementsMember 2024-12-31 0001512762 us-gaap:InProcessResearchAndDevelopmentMember 2024-12-31 0001512762 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001512762 us-gaap:FairValueInputsLevel3Member chrs:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001512762 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001512762 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001512762 chrs:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001512762 us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001512762 us-gaap:FairValueInputsLevel3Member chrs:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2023-12-31 0001512762 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0001512762 chrs:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2024-01-01 2024-12-31 0001512762 us-gaap:RoyaltyAgreementsMember 2024-01-01 2024-12-31 0001512762 us-gaap:RoyaltyAgreementsMember 2024-12-31 0001512762 us-gaap:RoyaltyAgreementsMember 2024-05-08 0001512762 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember chrs:UdenycaBusinessMember 2024-01-01 2024-12-31 0001512762 chrs:YusimryImmunologyFranchiseMember 2023-01-01 2023-12-31 0001512762 chrs:UdenycaBusinessMember 2023-01-01 2023-12-31 0001512762 chrs:CimerliOphthalmologyFranchiseMember 2023-01-01 2023-12-31 0001512762 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember chrs:YusimryImmunologyFranchiseMember 2023-12-31 0001512762 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember chrs:CimerliOphthalmologyFranchiseMember 2023-12-31 0001512762 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember chrs:YusimryImmunologyFranchiseMember 2024-12-31 0001512762 srt:MaximumMember chrs:Plan401KMember 2019-01-01 2019-12-31 0001512762 srt:MaximumMember chrs:Plan401KMember 2024-01-01 2024-12-31 0001512762 chrs:Plan401KMember 2024-01-01 2024-12-31 0001512762 chrs:Plan401KMember 2023-01-01 2023-12-31 0001512762 chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member 2025-05-15 0001512762 chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member 2025-04-15 0001512762 chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member 2025-05-15 2025-05-15 0001512762 chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member us-gaap:ConvertibleDebtMember 2024-12-31 0001512762 2024-10-01 2024-12-31 0001512762 chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member 2025-06-30 0001512762 chrs:TwoThousandTwentyNineTermLoansMember us-gaap:FairValueInputsLevel2Member 2024-12-31 0001512762 chrs:TermLoansMember us-gaap:SegmentDiscontinuedOperationsMember 2024-12-31 0001512762 chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member us-gaap:FairValueInputsLevel2Member 2024-12-31 0001512762 chrs:TermLoansMember 2024-12-31 0001512762 chrs:AnkuraTrustCompanyLlcMember chrs:TwoThousandTwentyNineTermLoansMember 2024-05-08 0001512762 chrs:TermLoansMember 2024-04-01 0001512762 chrs:TermLoansMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001512762 chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member us-gaap:FairValueInputsLevel2Member 2023-12-31 0001512762 us-gaap:ScenarioPlanMember chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member us-gaap:ConvertibleDebtMember 2024-01-01 2024-12-31 0001512762 chrs:McKessonMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0001512762 chrs:CardinalMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0001512762 chrs:AmeriSourceBergenCorpMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0001512762 chrs:McKessonMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001512762 chrs:CardinalMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001512762 chrs:AmeriSourceBergenCorpMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001512762 us-gaap:CommonStockMember 2024-12-31 0001512762 us-gaap:CommonStockMember 2023-12-31 0001512762 us-gaap:CommonStockMember 2022-12-31 0001512762 chrs:PublicOfferingMember 2023-05-16 0001512762 chrs:TwoThousandTenPlanMember 2024-12-31 0001512762 chrs:TwoThousandAndFourteenEquityIncentiveAwardPlanMember 2024-12-31 0001512762 chrs:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2024-12-31 0001512762 chrs:TwoThousandAndFourteenEquityIncentiveAwardPlanMember 2024-05-29 0001512762 chrs:SurfaceOncologyInc.Member us-gaap:LicensingAgreementsMember 2023-09-08 0001512762 chrs:SurfaceOncologyInc.Member us-gaap:InProcessResearchAndDevelopmentMember 2023-09-08 0001512762 chrs:SurfaceOncologyInc.Member chrs:OutLicensesWithNovartisInstitutesMember 2023-09-08 0001512762 chrs:SurfaceOncologyInc.Member chrs:OutLicensesWithGrkMember 2023-09-08 0001512762 chrs:SurfaceOncologyInc.Member chrs:InProcessResearchAndDevelopmentSrf388Member 2023-09-08 0001512762 chrs:SurfaceOncologyInc.Member chrs:InProcessResearchAndDevelopmentChs114Member 2023-09-08 0001512762 2025-04-30 0001512762 chrs:SurfaceOncologyInc.Member 2024-12-31 0001512762 chrs:SurfaceOncologyInc.Member 2024-03-31 0001512762 chrs:SurfaceOncologyInc.Member 2024-01-01 2024-03-31 0001512762 chrs:SurfaceOncologyInc.Member 2023-01-01 2023-12-31 0001512762 us-gaap:MoneyMarketFundsMember 2024-12-31 0001512762 us-gaap:MoneyMarketFundsMember 2023-12-31 0001512762 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001512762 us-gaap:CorporateNoteSecuritiesMember 2023-12-31 0001512762 us-gaap:USTreasurySecuritiesMember 2023-12-31 0001512762 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001512762 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001512762 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2023-12-31 0001512762 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001512762 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001512762 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001512762 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001512762 chrs:PrepaidExpensesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001512762 chrs:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2023-12-31 0001512762 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001512762 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001512762 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2023-12-31 0001512762 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001512762 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001512762 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001512762 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001512762 chrs:PrepaidExpensesMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001512762 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001512762 chrs:LaboratoryFacilitiesLeaseAgreementMember 2023-12-31 0001512762 chrs:CorporateHeadquartersLeaseAgreementMember 2023-12-31 0001512762 chrs:OfficeSpaceRemainingPremisesMember chrs:SixthAmendmentToLeaseMember 2023-10-24 0001512762 chrs:SixthAmendmentToLeaseMember 2023-10-24 0001512762 chrs:ConvertibleNotesMember chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member 2024-01-01 2024-12-31 0001512762 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-12-31 0001512762 chrs:EmployeesAndNonemployeesStockOptionMember 2024-01-01 2024-12-31 0001512762 chrs:ConvertibleNotesMember chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member 2023-01-01 2023-12-31 0001512762 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001512762 chrs:EmployeesAndNonemployeesStockOptionMember 2023-01-01 2023-12-31 0001512762 chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member us-gaap:ConvertibleDebtMember 2024-01-01 2024-12-31 0001512762 chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member us-gaap:ConvertibleDebtMember 2023-01-01 2023-12-31 0001512762 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-12-31 0001512762 us-gaap:SegmentDiscontinuedOperationsMember 2024-01-01 2024-12-31 0001512762 us-gaap:SegmentContinuingOperationsMember 2024-01-01 2024-12-31 0001512762 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-12-31 0001512762 us-gaap:CostOfSalesMember 2024-01-01 2024-12-31 0001512762 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-12-31 0001512762 us-gaap:SegmentDiscontinuedOperationsMember 2023-01-01 2023-12-31 0001512762 us-gaap:SegmentContinuingOperationsMember 2023-01-01 2023-12-31 0001512762 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0001512762 chrs:SurfaceOncologyInc.Member chrs:OutLicensesWithNovartisInstitutesMember 2023-09-08 2023-09-08 0001512762 chrs:SurfaceOncologyInc.Member chrs:OutLicensesWithGrkMember 2023-09-08 2023-09-08 0001512762 chrs:JunshiBiosciencesMember 2024-12-31 0001512762 srt:WeightedAverageMember chrs:AtMarketOfferingMember 2024-01-01 2024-12-31 0001512762 srt:WeightedAverageMember chrs:AtMarketOfferingMember 2023-01-01 2023-12-31 0001512762 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember chrs:CimerliOphthalmologyFranchiseMember 2024-12-31 0001512762 chrs:ScenarioNetSalesExceeding350MillionQuartersEndingMarch312027Member us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember chrs:UdenycaBusinessMember 2025-04-11 2025-04-11 0001512762 chrs:ScenarioNetSalesExceeding300MillionQuartersEndingSeptember302026Member us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember chrs:UdenycaBusinessMember 2025-04-11 2025-04-11 0001512762 us-gaap:DomesticCountryMember us-gaap:ResearchMember 2024-01-01 2024-12-31 0001512762 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001512762 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001512762 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001512762 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0001512762 chrs:YusimryProductMember 2023-01-01 2023-12-31 0001512762 us-gaap:OverAllotmentOptionMember 2023-05-16 2023-05-16 0001512762 chrs:AtMarketOfferingMember 2023-05-15 0001512762 srt:MaximumMember chrs:AtMarketOfferingMember 2023-09-11 0001512762 srt:MaximumMember chrs:PublicOfferingMember 2023-05-16 0001512762 srt:MaximumMember chrs:AtMarketOfferingMember 2023-05-15 0001512762 srt:MaximumMember chrs:AtMarketOfferingMember 2022-11-08 0001512762 us-gaap:EmployeeSeveranceMember 2023-01-01 2023-03-31 0001512762 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-12-31 0001512762 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001512762 chrs:RevenuePurchaseAndSaleAgreementMember 2024-01-01 2024-12-31 0001512762 chrs:TermLoansMember 2024-01-01 2024-12-31 0001512762 chrs:RevenuePurchaseAndSaleAgreementMember 2025-01-01 2025-03-31 0001512762 chrs:UdenycaMember chrs:RevenuePurchaseAndSaleAgreementMember 2024-05-08 0001512762 chrs:UdenycaAndLoqtorziMember chrs:RevenuePurchaseAndSaleAgreementMember 2024-05-08 0001512762 chrs:RevenuePurchaseAndSaleAgreementMember 2024-05-08 0001512762 chrs:RebatesMember 2024-12-31 0001512762 chrs:OtherFeesCoPayAssistanceAndReturnsMember 2024-12-31 0001512762 chrs:ChargebacksAndDiscountsForPromptPaymentMember 2024-12-31 0001512762 chrs:RebatesMember 2023-12-31 0001512762 chrs:OtherFeesCoPayAssistanceAndReturnsMember 2023-12-31 0001512762 chrs:ChargebacksAndDiscountsForPromptPaymentMember 2023-12-31 0001512762 chrs:RebatesMember 2022-12-31 0001512762 chrs:OtherFeesCoPayAssistanceAndReturnsMember 2022-12-31 0001512762 chrs:ChargebacksAndDiscountsForPromptPaymentMember 2022-12-31 0001512762 2022-12-31 0001512762 srt:MinimumMember chrs:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2014-10-31 2014-10-31 0001512762 chrs:TwoThousandAndFourteenEquityIncentiveAwardPlanMember 2024-01-01 2024-12-31 0001512762 us-gaap:MachineryAndEquipmentMember 2024-12-31 0001512762 us-gaap:LeaseholdImprovementsMember 2024-12-31 0001512762 us-gaap:FurnitureAndFixturesMember 2024-12-31 0001512762 us-gaap:ComputerEquipmentMember 2024-12-31 0001512762 us-gaap:MachineryAndEquipmentMember 2023-12-31 0001512762 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2023-12-31 0001512762 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001512762 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001512762 us-gaap:ComputerEquipmentMember 2023-12-31 0001512762 chrs:AtMarketOfferingMember 2024-01-01 2024-12-31 0001512762 chrs:AtMarketOfferingMember 2023-01-01 2023-12-31 0001512762 chrs:LoqtorziMember 2024-12-31 0001512762 chrs:LoqtorziMember 2019-05-02 0001512762 chrs:BioeqIPAGMember 2019-11-04 2019-11-04 0001512762 srt:MinimumMember 2024-01-01 2024-12-31 0001512762 srt:MaximumMember 2024-01-01 2024-12-31 0001512762 chrs:RevenuePurchaseAndSaleAgreementMember chrs:UdenycaBusinessMember 2025-04-15 2025-04-15 0001512762 chrs:RebatesMember 2024-01-01 2024-12-31 0001512762 chrs:OtherFeesCoPayAssistanceAndReturnsMember 2024-01-01 2024-12-31 0001512762 chrs:ChargebacksAndDiscountsForPromptPaymentMember 2024-01-01 2024-12-31 0001512762 chrs:RebatesMember 2023-01-01 2023-12-31 0001512762 chrs:OtherFeesCoPayAssistanceAndReturnsMember 2023-01-01 2023-12-31 0001512762 chrs:ChargebacksAndDiscountsForPromptPaymentMember 2023-01-01 2023-12-31 0001512762 us-gaap:StateAndLocalJurisdictionMember 2024-01-01 2024-12-31 0001512762 us-gaap:DomesticCountryMember 2024-01-01 2024-12-31 0001512762 chrs:VehiclesLeaseMember 2019-01-01 2019-12-31 0001512762 chrs:ChiefMarketingOfficerMember chrs:OptionalStockPurchaseAgreementMember 2023-10-04 2023-10-04 0001512762 chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member 2024-12-31 0001512762 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember chrs:UdenycaBusinessMember 2025-04-11 0001512762 2024-02-05 2024-02-05 0001512762 chrs:ToripalimabMember chrs:JunshiBiosciencesMember 2024-01-01 2024-12-31 0001512762 2024-03-01 2024-03-31 0001512762 us-gaap:LicenseMember chrs:JunshiBiosciencesMember 2021-02-01 2021-02-01 0001512762 chrs:TwoThousandTwentyNineTermLoansMember 2024-12-31 0001512762 us-gaap:CostOfSalesMember 2023-01-01 2023-12-31 0001512762 chrs:TwoThousandTwentyNineTermLoansMember us-gaap:DebtInstrumentRedemptionPeriodTwoMember 2024-05-08 2024-05-08 0001512762 chrs:TwoThousandTwentyNineTermLoansMember us-gaap:DebtInstrumentRedemptionPeriodThreeMember 2024-05-08 2024-05-08 0001512762 chrs:TwoThousandTwentyNineTermLoansMember us-gaap:DebtInstrumentRedemptionPeriodOneMember 2024-05-08 2024-05-08 0001512762 chrs:RevenuePurchaseAndSaleAgreementMember chrs:UdenycaBusinessMember us-gaap:InterestExpenseMember 2024-01-01 2024-12-31 0001512762 chrs:RevenuePurchaseAndSaleAgreementMember us-gaap:InterestExpenseMember 2024-01-01 2024-12-31 0001512762 chrs:AtMarketOfferingMember 2023-09-11 2023-09-11 0001512762 chrs:SurfaceOncologyInc.Member chrs:OutLicensesWithNovartisInstitutesMember 2024-01-01 2024-03-31 0001512762 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember chrs:CimerliOphthalmologyFranchiseMember 2024-03-01 2024-03-01 0001512762 chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member us-gaap:ConvertibleDebtMember 2020-04-01 2020-04-30 0001512762 chrs:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2014-10-31 2014-10-31 0001512762 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember chrs:UdenycaBusinessMember 2025-04-11 2025-04-11 0001512762 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember chrs:YusimryImmunologyFranchiseMember 2024-01-01 2024-12-31 0001512762 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember chrs:CimerliOphthalmologyFranchiseMember 2024-01-01 2024-12-31 0001512762 us-gaap:DiscontinuedOperationsHeldforsaleMember 2024-12-31 0001512762 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2024-01-01 2024-12-31 0001512762 us-gaap:DiscontinuedOperationsHeldforsaleMember 2023-12-31 0001512762 us-gaap:DiscontinuedOperationsHeldforsaleMember chrs:YusimryImmunologyFranchiseAndCimerliOphthalmologyFranchiseMember 2023-01-01 2023-12-31 0001512762 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember chrs:YusimryImmunologyFranchiseMember 2024-06-26 0001512762 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember chrs:YusimryImmunologyFranchiseAndCimerliOphthalmologyFranchiseMember 2024-01-01 2024-12-31 0001512762 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember chrs:CimerliOphthalmologyFranchiseMember 2024-03-01 0001512762 chrs:RevenuePurchaseAndSaleAgreementMember 2024-12-31 0001512762 chrs:ScenarioNetSalesExceeding350MillionQuartersEndingMarch312027Member us-gaap:DiscontinuedOperationsDisposedOfBySaleMember chrs:UdenycaBusinessMember 2025-04-11 0001512762 chrs:ScenarioNetSalesExceeding300MillionQuartersEndingSeptember302026Member us-gaap:DiscontinuedOperationsDisposedOfBySaleMember chrs:UdenycaBusinessMember 2025-04-11 0001512762 chrs:JunshiBiosciencesMember 2024-01-01 2024-12-31 0001512762 2024-02-05 0001512762 chrs:BiopharmaCreditInvestmentsVGpLlcMember chrs:TermLoansMember 2024-05-08 0001512762 chrs:BiopharmaCreditInvestmentsVGpLlcMember chrs:TermLoansMember 2022-01-05 0001512762 chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member us-gaap:ConvertibleDebtMember 2020-04-30 0001512762 chrs:TwoThousandTwentyNineTermLoansMember 2024-01-01 2024-12-31 0001512762 chrs:ConvertibleSeniorSubordinatedNotesDue20261.5Member 2024-01-01 2024-12-31 0001512762 chrs:TwoThousandTwentyNineTermLoansMember 2024-05-08 2024-05-08 0001512762 chrs:TermLoansMember 2024-04-01 2024-04-01 0001512762 chrs:AtMarketOfferingMember 2024-12-31 0001512762 chrs:ToripalimabMember chrs:JunshiBiosciencesMember 2021-02-01 2021-02-01 0001512762 chrs:Chs006AntiTigitAntibodyMember 2021-02-01 0001512762 chrs:CanadaLicenseAgreementMember 2024-01-01 2024-12-31 0001512762 chrs:Chs006AntiTigitAntibodyMember 2022-03-01 2022-03-31 0001512762 chrs:Chs006AntiTigitAntibodyMember 2021-02-01 2021-02-01 0001512762 chrs:JunshiBiosciencesMember 2021-02-01 2021-02-01 0001512762 chrs:SurfaceMember chrs:GskAgreementMember 2022-03-01 2022-03-31 0001512762 chrs:AntiTigitAntibodyAndIl2CytokineMember chrs:Chs006AntiTigitAntibodyMember 2022-03-31 0001512762 chrs:ToripalimabMember chrs:JunshiBiosciencesMember 2024-12-31 0001512762 chrs:VaccinexLicenseAgreementMember 2021-03-23 2021-03-23 0001512762 chrs:AdimabDevelopmentAndOptionAgreementMember 2018-10-01 2018-10-31 0001512762 chrs:GskAgreementMember 2020-12-01 2020-12-31 0001512762 us-gaap:AccountsPayableMember chrs:JunshiBiosciencesMember 2024-12-31 0001512762 chrs:AccruedAndOtherCurrentLiabilitiesMember chrs:JunshiBiosciencesMember 2024-12-31 0001512762 us-gaap:AccountsPayableMember chrs:JunshiBiosciencesMember 2023-12-31 0001512762 chrs:AccruedAndOtherCurrentLiabilitiesMember chrs:JunshiBiosciencesMember 2023-12-31 0001512762 us-gaap:CallOptionMember 2020-04-01 2020-04-30 0001512762 2023-01-01 2023-12-31 0001512762 chrs:SurfaceOncologyInc.Member 2023-09-08 0001512762 chrs:SurfaceOncologyInc.Member chrs:SurfaceSrf388ProprietaryDrugProductAgreementMember 2023-09-08 2023-09-08 0001512762 chrs:SurfaceOncologyInc.Member chrs:SurfaceSrf114ProprietaryDrugProductAgreementMember 2023-09-08 2023-09-08 0001512762 chrs:SurfaceOncologyInc.Member chrs:SurfaceGlaxosmithklineAgreementMember 2023-09-08 2023-09-08 0001512762 chrs:SurfaceOncologyInc.Member 2023-09-08 2023-09-08 0001512762 us-gaap:LicenseMember chrs:BioeqIPAGMember 2022-01-01 2022-12-31 0001512762 2024-01-01 2024-12-31 0001512762 chrs:IntangibleAssetsNetAndAccruedAndOtherCurrentLiabilitiesMember chrs:JunshiBiosciencesMember 2024-03-31 0001512762 chrs:JunshiBiosciencesMember 2023-10-27 0001512762 2024-12-31 0001512762 2023-12-31 0001512762 chrs:DiscontinuedOperationsClassifiedAsNotHeldForSaleMember 2024-12-31 0001512762 chrs:DiscontinuedOperationsClassifiedAsNotHeldForSaleMember 2023-12-31 chrs:position chrs:employee iso4217:USD iso4217:EUR xbrli:pure chrs:item xbrli:shares iso4217:USD xbrli:shares chrs:payment chrs:segment utr:sqft

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

​

FORM 8-K

​

​

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): November 13, 2025

​

​

COHERUS ONCOLOGY, INC.

(Exact name of registrant as specified in its charter)

​

​

Delaware |  | 001-36721 |  | 27-3615821
(State or other jurisdiction of incorporation) |  | (Commission File Number) |  | (IRS Employer Identification Number)

​

333 Twin Dolphin Drive, Suite 600

Redwood City, CA 94065

(Address of principal executive offices, including Zip Code)

​

Registrant’s telephone number, including area code: (650) 649-3530

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
​ | ​
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
​ | ​
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
​ | ​
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
Common Stock, $0.0001 par value per share |  | CHRS |  | The Nasdaq Global Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

​

​

Item 8.01 Other Events.

Coherus Oncology, Inc. (the “Company”) is filing this Current Report on Form 8-K (this “Form 8-K”), including Exhibit 99.1, solely to recast certain financial information and related disclosures included in the Company’s Annual Report on Form 10-K for the fiscal year ending December 31, 2024 originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 17, 2025 (the “2024 Form 10-K”) to provide retrospective discontinued operations presentation for the years ended December 31, 2024 and 2023 reflected in the 2024 Form 10-K. The recast financial information is attached as Exhibit 99.1 to this Current Report on Form 8-K, which the Company intends to incorporate by reference into a registration statement on Form S-3 expected to be filed by the Company on November 13, 2025.

On December 2, 2024, the Company and Intas Pharmaceuticals Ltd. (“Intas”) entered into an asset purchase agreement (the “UDENYCA Purchase Agreement”), pursuant to which, and upon the terms and subject to the conditions thereof, the Company agreed to divest the UDENYCA franchise (the “UDENYCA Business”) to Intas (the “UDENYCA Sale”). On April 11, 2025, the Company completed the divestiture of the UDENYCA Business to Intas for upfront, all-cash consideration of $483.4 million, inclusive of $118.4 million for UDENYCA product inventory. In addition, the Company is also eligible to receive two additional earn-out payments of $37.5 million each.

The UDENYCA Sale represented the last and most significant divestiture of the Company’s biosimilar businesses, which comprised the UDENYCA, YUSIMRY and CIMERLI franchises; representing a strategic shift resulting in a major effect on the Company’s business and therefore met the criteria for classification as discontinued operations. Accordingly, starting with the Company’s Quarterly Report on Form 10-Q for the quarter ending March 31, 2025, the Company began to classify its condensed consolidated financial statements as discontinued operations for all periods presented. The Company’s consolidated financial statements, recast to reflect the retrospective presentation of discontinued operations for the fiscal years ended December 31, 2024 and 2023, are presented within Exhibit 99.1 to this Current Report on Form 8-K

In order to preserve the nature and character of the disclosures set forth in the 2024 Form 10-K, the items included in Exhibit 99.1 to this Form 8-K have been updated solely for matters relating specifically to the treatment of the Company’s biosimilar businesses as discontinued operations. This Form 8-K does not reflect other events occurring after the filing date of the 2024 Form 10-K, except as otherwise reflected in Exhibit 99.1. Unless otherwise noted, applicable amounts in the comparative periods have been recast to conform to this discontinued operations presentation. This Form 8-K should be read in conjunction with the 2024 Form 10-K and the filings with the SEC made by the Company after the filing of the 2024 Form 10-K, including the Company’s Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2025, June 30, 2025 and September 30, 2025, and the other filings with the SEC made by the Company after the filing of the 2024 Form 10-K.

The following items of the 2024 Form 10-K have been recast to reflect the retrospective presentation of discontinued operations as shown in Exhibit 99.1 to this Form 8-K:

| ● | Part II, Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations”

| ● | Part II, Item 7A. “Quantitative and Qualitative Disclosures About Market Risk” and

| ● | Part II, Item 8. “Financial Statements and Supplementary Data”

​

​

​

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

​

​ | ​ | ​
Exhibit No. |  | Description
​ | ​ | ​
23.1 | ​ | Consent of Independent Registered Public Accounting Firm
​ | ​ | ​
99.1 | ​ | Updated Part II, Items 7. and 7A. “Management’s Discussion and Analysis of Financial Condition and Results of Operations and Quantitative and Qualitative Disclosures About Market Risk,” and Part II, Item 8. “Financial Statements and Supplementary Data” of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 ​
101.INS ​ ​ 101.SCH ​ 101.CAL ​ 101.DEF ​ 101.LAB ​ 101.PRE ​ | ​ | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document ​ Inline XBRL Taxonomy Extension Schema Document ​ Inline XBRL Taxonomy Extension Calculation Linkbase Document ​ Inline XBRL Taxonomy Extension Definition Linkbase Document ​ Inline XBRL Taxonomy Extension Label Linkbase Document ​ Inline XBRL Taxonomy Extension Presentation Linkbase Document ​
104 | ​ | Cover page Interactive Data file (embedded within the Inline XBRL document)

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​ | ​ | ​ | ​
Date: November 13, 2025 |  | COHERUS ONCOLOGY, INC.
​ | ​ | ​ | ​
​ | ​ | By: | /s/ Dennis M. Lanfear
​ | ​ | Name: | Dennis M. Lanfear
​ | ​ | Title: | Chief Executive Officer

​

​

​

​